ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 0757 • ACR Convergence 2020

    Sunlight Exposure, Sun-protective Behaviour, and Anti-citrullinated Protein Antibody Positivity: A General Population-based Study in Quebec, Canada

    Naizhuo Zhao1, Audrey Smargiassi2, Ines Colmegna3, Marie Hudson4, Marvin Fritzler5 and Sasha Bernatsky6, 1McGill University, Montreal, Canada, 2l’Université de Montréal, Montreal, Canada, 3The Research Institute of the McGill University Health Centre, Montreal, Canada, 4Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, 5Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 6The Research Institute of the McGill University Health Centre, Montreal, ON, Canada

    Background/Purpose: Sunlight exposure has been associated with lower rheumatoid arthritis (RA) risk, but to our knowledge, no one has ever studied sunlight exposure and anti-citrullinated…
  • Abstract Number: 0775 • ACR Convergence 2020

    T and B Cell Responses to Common Tenascin-C Peptides in RA

    JING Song1, Anja Schwenzer2, Sara Turcinov3, Alicia Wong2, Cliff Rims1, Lorena Rodriguez Martinez2, David Arribas-Layton4, Christina Gerstner5, Virginia Muir6, Jeffrey Carlin7, Kim Midwood2, Vivianne Malmström8, Eddie James1 and Jane Buckner1, 1Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, 2Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 3Division of Rheumatology, Department of Medicine,Center for Molecular Medicine, Institutet, Stockholm, Sweden, 4Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, 5Division of Rheumatology, Department of Medicine,Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, 6Center for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, 7Department of Rheumatology, Virginia Mason Medical Center, Seattle, WA, 8Karolinska Institutet, Stockholm, Stockholms Lan, Sweden

    Background/Purpose: Although autoreactive CD4+ T cell and antibody responses against citrullinated antigens are known to contribute to loss of immune tolerance in rheumatoid arthritis (RA),…
  • Abstract Number: 0792 • ACR Convergence 2020

    LY294002 Improves the Collagen-induced Arthritis by Inducing Neutrophil Apoptosis

    Xuechan Huang1, Tianwang Li1, Shuyang Chen1, Zhixiang Huang1 and Junming Chen1, 1Department of Rheumatology and Immunology, Guangdong Second Provincial General Hospital, Guangdong, China (People's Republic)

    Background/Purpose: Neutrophils play a central role in host defense, but they also play important effectors on acute and chronic inflammation. Neutrophil apoptosis is essential for…
  • Abstract Number: 0808 • ACR Convergence 2020

    Time to Discontinuation of Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients with and Without Methotrexate: Real World Results from a Rheumatoid Arthritis Cohort

    Mohammad Movahedi1, Angela Cesta2, Xiuying Li3, Edward C Keystone4 and Claire Bombardier5, 1Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 2Toronto General Hospital Research Institute, Toronto, ON, Canada, 3Toronto General Hospital Research Institute, Toronto, Canada, 4Mount Sinai Hospital, Toronto, ON, Canada, 5Institute for Work and Health, Toronto, ON, Canada

    Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment and is prescribed alone or with methotrexate (MTX). TOFA can…
  • Abstract Number: 0825 • ACR Convergence 2020

    Sex Differences in the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis Patients: A Post Hoc Analysis of Phase 3 and Long-Term Extension Trials

    Niall Jones1, Vibeke Strand2, Hendrik Schulze-Koops3, Eduardo Mysler4, Cassandra D Kinch5, David Gruben6, Rebecca Germino7, Carol A Connell6 and Lihi Eder8, 1Division of Rheumatology, University of Alberta, Edmonton, AB, Canada, 2Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, 3Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, 4Organización Médica de Investigación, Buenos Aires, Argentina, 5Pfizer Canada ULC, Kirkland, QC, Canada, 6Pfizer Inc, Groton, CT, 7Pfizer Inc, New York, NY, 8Women’s College Research Institute, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Differences in efficacy outcomes favoring male vs female patients (pts) with RA have been reported with csDMARDs1 and TNF inhibitors;2 results with JAK inhibitors…
  • Abstract Number: 0968 • ACR Convergence 2020

    Combined Inhibition of Autophagy and Glutamine Metabolism Suppresses Cell Growth of RA Synoviocytes and Ameliorates Arthritis in SKG Mice

    Ikuko Naka1, Jun Saegusa2, Kenichi Uto2, Yuzuru Yamamoto3, Yoshihide Ichise4, Hirotaka Yamada4, Yo Ueda5, Takaichi Okano4, Soshi Takahashi6, Sho Sendo7 and Akio Morinobu8, 1Kobe University, Kobe, 2Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan, 3Kobe University, Kobe-city, Japan, 4Kobe University, Kobe, Japan, 5Kobe UniversityRheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan, 6Kobe univerity, Kobe, Japan, 7Kobe university, Kobe city, Japan, 8Rheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan

    Background/Purpose: Immunometabolism is now recognaized to be crucial in the pathogenesis of rheumatoid arthritis (RA). We have recently shown that the expression of glutaminase 1…
  • Abstract Number: 1006 • ACR Convergence 2020

    Post-menopausal Rheumatoid Arthritis Is Inversely Associated with Lifetime High Level of Estrogen Exposure in the French E3N Cohort

    Carine Salliot1, Yann Nguyen2, Amandine Gelot3, Xavier Mariette4, Marie-Christine Boutron-Ruault3 and Raphaèle Seror5, 1CHR orleans, Orleans, France, 21Department of Internal Medicine, Hôpital Beaujon, APHP Nord, Université de Paris, Clichy, Clichy, France, 3Institut Gustave Roussy, Villejuif, France, 4Paris-Sud University, Rueil-Malmaison, France, 5Rheumatology Department, Bicetre Hospital, APHP, France, Paris, France

    Background/Purpose: The involvement of female hormones in the pathogenesis of Rheumatoid Arthritis (RA) is supported by numerous observations: a female predominance, an increased incidence in…
  • Abstract Number: 1141 • ACR Convergence 2020

    Reversing Seasonal Decline of T2T Outcome in RA Patients Under Double Hits by Chinese New Year and COVID-19 Epidemic via Online Interaction with SSDM

    Rong Mu1, Hongbin Li2, Zhanyun Da3, Anbin Huang4, Hongzhi Wang5, Jing Lu6, Jianhong Wu7, Shengtao Zhang8, Yikai Yu9, Chun Li10, Shouxin Li9, Peng Ji11, Hua Wei12, Bin Wu13, Zhenbin Li14, Lingxun Shen15, Yanping Zhao16, Yi Zhao17, Xiaoqiang Hou18, Hui Xiao19, Yuhua Jia20, Bing Wu20, Yonggang Zhao20, Xin Chen19, Miaomiao Song20, Fei Xiao20 and Zhanguo Li21, 1People's Hospital, Beijing University Medical School, Beijing, Beijing, China (People's Republic), 2The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China (People's Republic), 3The affiliated Hospital of Nantong University, Nantong, Jiangsu, China (People's Republic), 4Union Hospital Affiliated Tongji Medical College of Huazhong University of Science and Technology, WuHan, China (People's Republic), 5The First Hospital of Jiaxing, Jiaxing, China (People's Republic), 6First Affiliated Hospital of China Medical University, Shenyang, China (People's Republic), 7Department of Rheumatology, Dazhou Central Hospital, Dazhou, China (People's Republic), 8Tongji Hospital Affiliated Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China (People's Republic), 9Tongji Hospital Affiliated to Tongji Medical College of HUST, Wuhan, Hubei, China (People's Republic), 10People's Hospital, Beijing University Medical School, beijing, China (People's Republic), 11The first affiliated hospital of xinjiang medical university, Urumqi, Xinjiang, China (People's Republic), 12Northern Jiangsu People's Hospital, Yangzhou, China (People's Republic), 13Chongqing Hospital of Traditional Chinese Medicine, chongqing, China (People's Republic), 14Chinese people ’s liberation army joint service support force 980 hospital, shijiazhuang, Jiangxi, China (People's Republic), 15Union Hospital Affiliated Tongji Medical College of HUST, Wuhan, Hubei, China (People's Republic), 16First Affiliated Hospital of Harbin Medical University, Harbin, China (People's Republic), 17Xuanwu Hospital, Capital Medical University, Beijing, China, Beijing, China (People's Republic), 18Yichang Central People's Hospital, Beijing, China (People's Republic), 19Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), 20Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China (People's Republic), 21Peking University People’s Hospital, Xicheng, Beijing, China (People's Republic)

    Background/Purpose: Treat-to-target (T2T), achieving a DAS28 below 3.2 is the main management strategy for RA. The Chinese New Year is a long holiday started in…
  • Abstract Number: 1193 • ACR Convergence 2020

    Unsupervised Molecular Profile Clustering in the Serum of Rheumatoid Arthritis Patients Identifies Groups with Differential CV-risk SCORE: Modulation by Biological Therapies

    Maria Luque-Tevar1, Carlos Pérez-Sánchez1, Pilar Font2, Alejandra Maria Patiño-Trives1, Montserrat Romero-Gomez2, Desirée Ruiz-Vilchez2, Sara Remuzgo-Martínez3, Raquel López-Mejías4, Iván Arias de la Rosa1, Carmen Torres-Granados1, María-Carmen Abalos-Aguilera1, Rafaela Ortega-Castro2, Alejandro Escudero-Contreras2, Carlos Rodriguez-Escalera5, Jose Perez-Venegas6, Mª Dolores Ruiz-Montesinos6, Carmen Dominguez6, Carmen Romero-Barco7, Antonio Fernandez-Nebro8, Natalia Mena-Vazquez9, Jose Luis Marenco10, Julia Uceda-Montañez10, Mª Dolores Toledo-Coello11, Nuria Barbarroja1, M Angeles Aguirre2, Eduardo Collantes2, Miguel A Gonzalez-Gay12 and Chary Lopez-Pedrera1, 1Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Cordoba, Spain, 2Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, 3Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL, Santander, Spain, 4Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, 5Hospital Universitario de Jaen, Jaén, Spain, 6Hospital Universitario Virgen Macarena, Sevilla, Sevilla, Spain, 7Hospital Clínico Universitario, Málaga, Málaga, Spain, 8University of Malaga, Malaga, Spain, 9Hospital Regional Universitario de Málaga, Málaga, Spain, 10Hospital Universitario Virgen de Valme, Sevilla, Sevilla, Spain, 11Hospital Universitario de Jerez de la Frontera, Cádiz, Spain, Cádiz, Spain, 12Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander

    Background/Purpose: To identify specific molecular profiles associated to the enhanced cardiovascular (CV)-risk present in Rheumatoid Arthritis (RA) patients and their modulation by biologic disease modifying…
  • Abstract Number: 1209 • ACR Convergence 2020

    The Strength of IL-6/STAT3 Signal Inhibition by SAR S.c q2w Showed Significantly Higher Level Than That of TCZ S.c q2w but Lower Than TCZ S.c q1w

    Shuntaro Saito1, Katsuya Suzuki2, Keiko Yoshimoto2, Yasushi Kondo2, Jun Kikuchi2, Kotaro Otomo2, Hironari Hanaoka2, Yuko Kaneko2 and Tsutomu Takeuchi3, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, 2Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 3Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan

    Background/Purpose: Interleukin-6 (IL-6) is a key cytokine in the pathogenesis of rheumatoid arthritis (RA). Tocilizumab (TCZ) and Sarilumab (SAR) are monoclonal antibodies that bind to…
  • Abstract Number: 1226 • ACR Convergence 2020

    Outcomes and Efficacy of Selective versus Automatic Switching from Etanercept to a Biosimilar in Inflammatory Arthritis Using Electronic Health Records from UK

    Roxanne Cooksey1, Sinead Brophy1, Muhammad Azizur1, Jonathan Kennedy1 and Ernest Choy2, 1Swansea University, Swansea, Wales, United Kingdom, 2CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom

    Background/Purpose: Biosimilars have been approved for the treatment of inflammatory arthritis and evidence from randomised controlled trials have demonstrated equivalent efficacy to biologics.  Etanercept biosimilar,…
  • Abstract Number: 1399 • ACR Convergence 2020

    Differential Impacts of TNFa Inhibitors on the Expression of Th Cytokines

    Ching-Huang Ho1, Andrea Silva1 and I-Cheng Ho2, 1Brigham and Women's Hospital, Boston, MA, 2Birgham and Women's Hospital, Boston, MA

    Background/Purpose: Inhibition of TNFα has emerged as an effective therapeutic approach for many autoimmune/inflammatory diseases.While the efficacy and safety profile of the five FDA-approved TNFis…
  • Abstract Number: 1477 • ACR Convergence 2020

    Adherence in Patients with Chronic Rheumatic Diseases Treated with Biological and Synthetic Targeted Therapies During COVID-19 Pandemic

    Patricia Castro Pérez1, Alberto Onteniente González1, Angel Aragón Díez1, Angel Gallegos Cid1, Jesús Garcia-Arroba Muñoz1 and Jose Manuel Rodriguez heredia1, 1Hospital de Getafe, Madrid, Spain

    Background/Purpose: Adherence to treatments for chronic rheumatic diseases is influenced by many factors, including the patient's belief in the development of adverse effects such as…
  • Abstract Number: 1551 • ACR Convergence 2020

    Rapid Effect of Tofacitinib in Reducing US Joint and Tendon Inflammatory Lesions of RA Patients: Data from a 24 Weeks Longitudinal Study

    Giuseppe Germanò1, Pierluigi Macchioni2, Giovanni Ciancio3, Filippo Crescentini1, Andrea Caruso2, Beatrice Maranini4, Sara Bonazza4, Gilda Sandri5, Maria Teresa Mascia5, Govoni Marcello4 and Carlo Salvarani6, 1Azienda USL-IRCCS di Reggio Emilia e Università di Modena e Reggio Emilia, REGGIO NELL'EMILIA, Emilia-Romagna, Italy, 2Azienda USL-IRCCS di Reggio Emilia e Università di Modena e Reggio Emilia, REGGIO NELL'EMILIA, Italy, 3Unità Operativa Complessa di Reumatologia Azienda Ospedaliero-Universitaria S. Anna -Ferrara, Ferrara, Emilia-Romagna, Italy, 4Unità Operativa Complessa di Reumatologia Azienda Ospedaliero-Universitaria S. Anna -Ferrara, Ferrara, Italy, 5Struttura Complessa di Reumatologia- Università di Modena e Reggio Emilia- Policlinico di Modena, Modena, Italy, 6Azienda USL-IRCCS di Reggio Emilia e Università di Modena e Reggio Emilia, Reggio Emilia, Italy

    Background/Purpose: To explore the effects of tofacitinib (Tofa) on US lesions in a consecutive series of patients with active RA MTX and/or bioDMARDs -IR. Methods: In…
  • Abstract Number: 1707 • ACR Convergence 2020

    Development and Delivery of Continuing Education Interventions Promoting Shared Decision Making in Rheumatoid Arthritis

    Richard Martin1, Marianna Shershneva2 and Lily Zurkovsky3, 1Michigan State University College of Human Medicine, Grand Rapids, MI, 2Senior Administrative Program Specialist, Office of Continuing Professional Development University of Wisconsin School of Medicine and Public Health, Madison, WI, 3Forefront Collaborative, Carmel, IN

    Background/Purpose: A core CMS policy goal is to improve patient experience by encouraging patient-centered care and shared decision making (SDM).  However, SDM techniques are underutilized…
  • « Previous Page
  • 1
  • …
  • 140
  • 141
  • 142
  • 143
  • 144
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology